Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group
Standard
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. / Lohse, Ansgar W; Sebode, Marcial; Jørgensen, Marianne H; Ytting, Henriette; Karlsen, Tom H; Kelly, Deirdre; Manns, Michael P; Vesterhus, Mette; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
in: J HEPATOL, Jahrgang 73, Nr. 6, 12.2020, S. 1496-1506.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group
AU - Lohse, Ansgar W
AU - Sebode, Marcial
AU - Jørgensen, Marianne H
AU - Ytting, Henriette
AU - Karlsen, Tom H
AU - Kelly, Deirdre
AU - Manns, Michael P
AU - Vesterhus, Mette
AU - European Reference Network on Hepatological Diseases (ERN RARE-LIVER)
N1 - Copyright © 2020. Published by Elsevier B.V.
PY - 2020/12
Y1 - 2020/12
N2 - Most patients with autoimmune hepatitis respond well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients who respond well to therapy have an excellent prognosis. However, insufficient response to standard therapy or intolerable side effects requiring dose adaptions or treatment changes occur in 10-20% of patients. While there is fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. Herein, the European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) outline a treatment algorithm for both children and adults that should help to standardise treatment approaches, in order to improve patient care and to enable the comparison of treatment results between scientific publications.
AB - Most patients with autoimmune hepatitis respond well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients who respond well to therapy have an excellent prognosis. However, insufficient response to standard therapy or intolerable side effects requiring dose adaptions or treatment changes occur in 10-20% of patients. While there is fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. Herein, the European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) outline a treatment algorithm for both children and adults that should help to standardise treatment approaches, in order to improve patient care and to enable the comparison of treatment results between scientific publications.
U2 - 10.1016/j.jhep.2020.07.023
DO - 10.1016/j.jhep.2020.07.023
M3 - SCORING: Review article
C2 - 32707224
VL - 73
SP - 1496
EP - 1506
JO - J HEPATOL
JF - J HEPATOL
SN - 0168-8278
IS - 6
ER -